Home
Conditions
Refractory Hairy Cell Leukemia

Clinical trial condition

Refractory Hairy Cell Leukemia

Explore clinical trials studying Refractory Hairy Cell Leukemia. Study availability and eligibility vary by location and protocol.

38 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Refractory Hairy Cell Leukemia trial results

Recruiting

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

NCT06965114

Conditions: Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations: NCI - Center for Cancer Research Bethesda, Maryland, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

University of Virginia Cancer Center Charlottesville, Virginia, United States

UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States

View Trial Details

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

NCT01815749

Conditions: Adult Grade III Lymphomatoid Granulomatosis, Blood Protein Disorders, Burkitt Lymphoma, +64 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, not recruiting

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

NCT01199562

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, +245 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Completed

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

NCT01384513

Conditions: Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), +111 more
Locations: Thomas Jefferson University Philadelphia, Pennsylvania, United States

View Trial Details

Completed

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

NCT04681105

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, Burkitt Lymphoma, +58 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Completed

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

NCT04578600

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +39 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

NCT01588015

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +198 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Completed

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

NCT02037256

Conditions: Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Blood Protein Disorders, +130 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Completed

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00489203

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +207 more
Locations: Hackensack University Medical Center Hackensack, New Jersey, United States

Fred Hutchinson Cancer Research Center Seattle, Washington, United States

View Trial Details

Completed

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

NCT01258998

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +82 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Refractory Hairy Cell Leukemia

Refractory Hairy Cell Leukemia trial results

Related conditions